- The companies will present pre-clinical data on Innate’s
lead ANKETTM asset, IPH6101/ SAR443579, the first NKp46/CD16-based
NK cell engager targeting CD123
- These data highlight molecule’s favorable safety profile in
non-human primates and potent antitumor activity against acute
myeloid leukemia (AML), including those resistant to antibody
dependent cell cytotoxicity (ADCC)
- These data support advancing IPH6101/ SAR443579 into the
clinic
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)
(“Innate” or the “Company”) announced that
pre-clinical data from its proprietary, multi-specific NK cell
engager platform, ANKETTM, will be presented at the Society for
Immunotherapy of Cancer (SITC) Annual Meeting in collaboration with
partner, Sanofi (poster #852).
Specifically, the companies will share new data on
IPH6101/SAR443579, the first NKp46/CD16-based NK cell engager using
Innate’s proprietary multi-specific antibody format1 that targets
CD123 on acute myeloid leukemia (AML) cells and now co-engages
NKp46 and CD16a on NK cells.
CD123 is an attractive target as it is expressed at high levels
in the majority of AML patients2. However, overcoming resistance to
antibody-dependent cellular cytotoxicity (ADCC) has been a
challenge.
In pre-clinical studies, IPH6101/SAR443579 demonstrated potent
antitumor activity against AML cell lines, including those
resistant to ADCC by a comparator anti-CD123 antibody.
IPH6101/SAR443579 also promoted strong and specific NK-cell
activation and induced cytokine secretion only in the presence of
AML target cells.
In addition, IPH6101/SAR443579 had sustained pharmacodynamic
effects in non-human primates, combining efficient depletion of
CD123-expressing cells with minor systemic cytokine release in
comparison to T-cell engagers. As expected, it also had a favorable
safety profile.
“There is a strong need to develop effective therapies to treat
acute myeloid leukemia, the most common acute leukemia in adults,”
said Pr. Eric Vivier, Ph.D., DVM, Chief Scientific Officer at
Innate Pharma. “We’re pleased to present pre-clinical data on
IPH6101/SAR443579 that shows antitumor activity against AML, and
more specifically, the potential of engaging NK cells through NKp46
and CD16 via our ANKETTM technology. We look forward to seeing
Sanofi dose the first patient in the clinic with this molecule
soon.”
Innate will also present a second ANKETTM poster (poster #851)
at SITC entitled, “Harnessing Innate Immunity in Cancer Therapies:
the Example of Natural Killer Cell Engagers.” The data will
highlight the induction of a unique NK cell activation pathway by
its tetra-specific ANKETTM molecule. The abstract can be accessed
here.
About ANKETTM:
ANKETTM (Antibody-based NK cell Engager
Therapeutics) is Innate's proprietary platform for
developing next-generation, multi-specific natural killer (NK) cell
engagers to treat certain types of cancer. The Company’s latest
innovation, its tetra-specific ANKETTM molecule, is the first NK
cell engager technology to engage activating receptors (NKp46 and
CD16), a tumor antigen and an interleukin-2 receptor (via an IL-2
variant, IL-2v) via a single molecule. This leverages the
advantages of harnessing NK cell effector functions against cancer
cells and also provides proliferation and activation signals
targeted to NK cells.
In pre-clinical studies, Innate's tri-1 and tetra-specific
ANKETTM technologies promote potent NK cell activation,
cytotoxicity and efficient control of tumor growth in pre-clinical
models. This versatile fit-for-purpose technology is creating an
entirely new class of molecules to induce synthetic immunity
against cancer.
About IPH6101/SAR443579:
In the first research program of the Sanofi collaboration,
IPH6101/SAR443579, the first NKp46/CD16-based NK cell engager using
Innate’s proprietary multi-specific antibody format1, has shown
antitumor activity in pre-clinical models, including supportive
pharmacokinetic/pharmacodynamic (PK/PD) and safety data in
non-human primate studies leading to its selection as a drug
candidate for development.
About the Innate-Sanofi agreement:
The Company has a research collaboration and licensing agreement
with Sanofi to apply Innate’s proprietary technology to the
development of innovative multi-specific antibody formats engaging
NK cells through the activating receptors NKp46 and CD16 to kill
tumor cells.
Under the terms of the license agreement, Sanofi will be
responsible for the development, manufacturing and
commercialization of products resulting from the research
collaboration. Innate Pharma will be eligible to up to €400m in
development and commercial milestone payments as well as royalties
on net sales.
About Innate Pharma:
Innate Pharma S.A. is a global, clinical-stage oncology-focused
biotech company dedicated to improving treatment and clinical
outcomes for patients through therapeutic antibodies that harness
the immune system to fight cancer.
Innate Pharma’s broad pipeline of antibodies includes several
potentially first-in-class clinical and preclinical candidates in
cancers with high unmet medical need.
Innate is a pioneer in the understanding of natural killer cell
biology and has expanded its expertise in the tumor
microenvironment and tumor-antigens, as well as antibody
engineering. This innovative approach has resulted in a diversified
proprietary portfolio and major alliances with leaders in the
biopharmaceutical industry including Bristol-Myers Squibb, Novo
Nordisk A/S, Sanofi, and a multi-products collaboration with
AstraZeneca.
Headquartered in Marseille, France with a US office in
Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq
in the US.
Learn more about Innate Pharma at www.innate-pharma.com
Information about Innate Pharma shares:
ISIN code Ticker code
LEI
FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk
factors:
This press release contains certain forward-looking statements,
including those within the meaning of the Private Securities
Litigation Reform Act of 1995.The use of certain words, including
“believe,” “potential,” “expect” and “will” and similar
expressions, is intended to identify forward-looking statements.
Although the company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, progression of and results from its ongoing and
planned clinical trials and preclinical studies, review and
approvals by regulatory authorities of its product candidates, the
Company’s commercialization efforts, the Company’s continued
ability to raise capital to fund its development and the overall
impact of the COVID-19 outbreak on the global healthcare system as
well as the Company’s business, financial condition and results of
operations. For an additional discussion of risks and uncertainties
which could cause the company's actual results, financial
condition, performance or achievements to differ from those
contained in the forward-looking statements, please refer to the
Risk Factors (“Facteurs de Risque") section of the Universal
Registration Document filed with the French Financial Markets
Authority (“AMF”), which is available on the AMF website or on
Innate Pharma’s website, and public filings and reports filed with
the U.S. Securities and Exchange Commission (“SEC”), including the
Company’s Annual Report on Form 20-F for the year ended December
31, 2020, and subsequent filings and reports filed with the AMF or
SEC, or otherwise made public, by the Company.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
_____________________
1 Gauthier et al. Cell (2019).
2 A Ehninger, M Kramer, C R�llig, C
Thiede, M Bornhäuser, M von Bonin, M Wermke, A Feldmann, M
Bachmann, G Ehninger, and U Oelschlägel, on behalf of the Study
Alliance Leukemia. Distribution and levels of cell surface
expression of CD33 and CD123 in acute myeloid leukemia. Blood
Cancer Journal. 2014 Jun; 4(6): e218. Published online 2014 Jun 13.
doi: 10.1038/bcj.2014.39.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211112005461/en/
Investors
Innate Pharma Henry Wheeler Tel.: +33 761 88 38 74
Henry.wheeler@innate-pharma.fr
Media
Innate Pharma Tracy Rossin (Global/US) Tel.: +1 240 801
0076 Tracy.Rossin@innate-pharma.com
ATCG Press Marie Puvieux (France) Tel.: +33 (0)9 81 87 46
72 innate-pharma@atcg-partners.com
Innate Pharma (EU:IPH)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Innate Pharma (EU:IPH)
Historical Stock Chart
Von Apr 2023 bis Apr 2024